Detailed price information for Cabaletta Bio Inc (CABA-Q) from The Globe and Mail including charting and trades.

Rese-cel myositis BLA submission on track for 2027 based on a 17-patient, single arm registrational cohort design, including an outpatient dosing ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Cabaletta Bio, Inc. (CABA) is a stock that can certainly grab the ...

First two GMP doses of rese-cel manufactured on the Cell Shuttle(TM) met all release specifications, were delivered on time, and have been infused into patients within Cabaletta Bio's RESET(TM) ...

Cabaletta Bio (CABA) drew fresh attention from investors after announcing encouraging clinical trial results for rese-cel in several autoimmune diseases. Presentations at the American College of ...

– Nine patients enrolled as of August 5, 2024 across the RESET™ clinical development program, including four since EULAR in June, with 22 U.S. clinical sites now enrolling – – Additional clinical data ...

Cabaletta Bio focuses on autoimmune diseases with a potential best-in-class cell therapy, CABA-201, showing promise in early studies. Its stock price rose >$25 due to positive data produced by a drug ...

PHILADELPHIA--(BUSINESS WIRE)--Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B ...

– Registrational cohort enrollment in RESET-Myositis™ trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis – – Five disease-specific cohorts fully enrolled in ...

Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient ...